| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 14, 2021 | Chicago gene therapy startup raises $139M | |
| Mar 16, 2021 | Gene editing specialist raises $150M | Gene editing startup Graphite Bio has picked up $150 million in new capital. RA Capital Management and Rock Springs Capital led the company's oversubscribed Series B, with backing from a host of new investors including Fidelity Management &... |
| Mar 1, 2021 | Gene therapy 3.0? Gene-coding startup launches with $20M | A new biotech is emerging from stealth to develop what its CEO calls "third-generation gene therapy."
Founded by former Human Genome Project researcher Joseph Higgins, SalioGen Therapeutics launched Monday with $20 million in Seri... |
| Feb 4, 2021 | Tencent leads USD 31 million Series C round into gene technology firm Vision Medicals | Guangzhou-based gene technology company Vision Medicals has completed a RMB 200 million (USD 31 million) Series C round led by Tencent and joined by existing investors including CICC Capital, CDH Investments, and CASH Capital, 36Kr reported... |
| Jan 19, 2021 | Vietnam’s genetic testing firm Gene Solutions ropes in KPMG to raise $20m | Premium
Vietnam-based genetic testing firm Gene Solutions is in talks to raise $20 million in a new funding round, and has roped in KPMG Vietnam as its deal advisor, according to a top executive of the firm.
Continue reading this story with... |
| Jan 6, 2021 | Bayer's VC arm leads $105M round for 'gene circuit' startup Senti Bio | Leaps by Bayer has led a chunky $105 million series B round for next-gen gene therapy player Senti Biosciences.
Sponsored by Agilent Technologies
How would you like to win free bench space at Lab Central for one scientist for an entire year... |
| Dec 16, 2020 | After leaving Wall Street to launch a gene therapy upstart, Rachel McMinn nabs $115M to drive her first candidate to the clinic | When former analyst Rachel McMinn started Neurogene from her apartment around three years ago, she would joke that they’d get office space as soon as her living room table was no longer big enough to hold company meetings.
“We ... |
| Oct 30, 2020 | News briefing: Axovant faces months of delay on lead Parkinson's gene therapy; Chinese CAR-T biotech nabs $100M | One of Axovant’s top gene therapy prospects for its second act is hitting a roadblock that could push its clinical timelines back by almost a year.
In an update, the biotech said it was informed about delays in CMC data and t... |
| Aug 5, 2020 | Taysha Gene Therapies $95M Series B brings biotech to the clinic | After announcing its launch with a large Seed round in April, a Dallas-based biotech startup has landed one of the largest funding rounds of the year so far to grow and bring some of its products to clinical trial.
Taysha Gene Therapies, a ... |
| Jul 2, 2020 | Biogen bags an AAV gene therapy program from Massachusetts Eye and Ear; Biotechs raised $1B-plus in latest round of follow-ons | → Biogen has picked up a new, preclinical gene therapy program from Massachusetts Eye and Ear for inherited retinal degeneration due to mutations in the PRPF31 gene, among the most common causes for autosomal domi... |
| Jun 24, 2020 | Gene regulation startup raises $700 million | Sign up for our daily briefingMake your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Enter your email address
Please enter a valid email.
Please enter a valid email.
Subscription failedSub... |
| May 1, 2020 | Taysha Gene Therapies: $30 Million Funding And UT Southwestern Partnership | Taysha Gene Therapies announced it raised $30 million in funding and signed a strategic partnership with UT Southwestern
Taysha Gene Therapies, a company that launched with a mission to eradicate severe and life-threatening monogenic diseas... |
| Apr 29, 2020 | Taysha Gene Therapies Raises $30M in Seed Financing | Taysha Gene Therapies, a Dallas, TX-based developer of treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system (CNS), raised $30m in seed funding.
The round was co-led by PBM Capital and Nolan Ca... |
| Apr 20, 2020 | Sofinnova Telethon Fund backs Naldini's gene therapy biotech; ORIC prices $75M IPO | → The Sofinnova Telethon Fund has found a new gene therapy upstart to back. The fund selected Genespire for its portfolio, tapping a biotech inspired by the work of Luigi Naldini, a legendary scientist in the field. The bio... |
| Feb 28, 2020 | Jim Wilson's gene therapy startup Passage Bio bucks market sentiments, raising upsized $216M IPO | A coronavirus fear-induced bloodbath on the Nasdaq has not stopped Passage Bio from making a public debut — and an exuberant one.
James Wilson
By pricing an upsized offering at $18, the top of the range, the gene therapy ... |
| Feb 12, 2020 | Prevail's gene therapy scores orphan, rare pediatric disease privileges; Germany's ITM secures €40M loan | → Prevail Therapeutics’ gene therapy for Gaucher disease now has both orphan drug and rare pediatric disease designations from the FDA. The latter was specifically for the treatment of neuronopathic Gaucher disease,... |
| Feb 5, 2020 | Ophthalmic gene therapy company Ikarovec launches with £2.5m seed funding | Ophthalmic gene therapy company Ikarovec launches with £2.5m seed funding
05-02-2020
Ikarovec, which is developing novel gene therapies to treat major ophthalmic indications, has launched today with £2.5m of seed funding from leading UK sta... |
| Nov 25, 2019 | Ferring and Blackstone Life Sciences Invest Over $570M In Novel Gene Therapy | SAINT-PREX, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ferring Pharmaceuticals and Blackstone Life Sciences today announced the joint investment of over $570 million USD in nadofaragene firadenovec (rAd-IFN/Syn3), an investigation... |
| Oct 24, 2019 | NIH, Gates Foundation invest $200M to develop gene therapies for developing countries | “This unprecedented collaboration focuses from the get-go on access, scalability and affordability of advanced gene-based strategies for sickle cell disease and HIV to make sure everybody, everywhere has the opportunity to be cured, not jus... |
| Aug 14, 2019 | Biotech targeting rare heart mutation with gene therapy scores $11M in Series A haul | While cardiovascular disease is the leading cause of death globally — it is cancer that has benefited most from strides in precision medicine. Now that cardiovascular-specific genetic mutations are being discove... |
| Apr 12, 2019 | Boulder-Based Gene Editing Company Inscripta Secures $20 Million | Boulder, Colorado-based gene editing company Inscripta announced it has increased its previously announced Series C funding round with $20 million from existing investors. This new funding round adds to the $85.5 million that the company an... |
| Jan 8, 2019 | China’s Morningside leads $40m funding in gene therapy developer Apic Bio | Premium
China’s early-stage investor Morningside Venture Capital has led a $40-million Series A investment in gene therapy company Apic Bio, which is developing treatment options for patients with rare genetic diseases.
Continue reading thi... |
| Aug 13, 2018 | Fresh from hauling in GSK’s budget-priced gene therapy group, Orchard harvests $150M mega-round. Is it time to IPO? | Just a few months ago Orchard Therapeutics was handed the opportunity of taking over GlaxoSmithKline’s gene therapy group, which had pushed the field’s second product, Strimvelis, to the European market — without seein... |
| May 16, 2018 | Startup developing single-letter gene editing technology launches with $87M Series A round | The Cambridge, Massachusetts-based firm, which had been in operation for about a year, is touting a “base editing” technology that allows editing of single letters in the genome – A (adenine), G (guanine), T (thymine) and C (cytosine) – rat... |
| Apr 3, 2018 | AstraZeneca wins priority review schedule for leukemia drug; Penn gene therapy upstart grabs $9.29M with Frazier's help | → AstraZeneca has won a priority review for its anti-CD22 therapy moxetumomab for hairy cell leukemia. The pharma giant can now expect a decision on third-line use in the third quarter, marking another prospective adva... |
| Feb 28, 2018 | Startup making Cas9 proxy for gene editing gets $55M to develop tools/software | Boulder-based startup Inscripta — which you might remember as the company that discovered a new CRISPR enzyme… and then gave it away for free — just landed $55.5 million in a Series C round.
Inscripta made headlines last De... |
| Feb 27, 2018 | NEA powers next-generation cell and gene therapy startup Senti to $53M series A round | New Enterprise Associates (NEA) has led a $53 million bet on the future of cell and gene therapies. The series A round sets up JLABS resident Senti Biosciences to use advances in synthetic biology to create more targeted, controllable thera... |
| Jan 3, 2018 | The gene therapy pricing debate gets real as Spark sets $850,000 charge for its pioneering drug | Years of debate, speculation and analysis have boiled down to this: Spark $ONCE Therapeutics has set an $850,000 wholesale acquisition cost for the US’s first gene therapy — $425,000 per eye damaged by an RPE65 gene mutatio... |
| Dec 20, 2017 | In gene therapy's second big win this week, Orchard nabs $110M Series B | London startup Orchard Therapeutics is joining the ranks of commercial-stage gene therapy companies with a new $110 million Series B round to take its lead program through late-stage trials.
The round was led by Baillie Gi... |
| Jun 28, 2017 | Gene therapy upstart lands $45M round; Biogen picks new communications chief | → A syndicate led by Arix Bioscience backed a big, $45 million round for LogicBio, an upstart gene therapy biotech focused on rare pediatric diseases. OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, and SBI... |
| Nov 22, 2016 | Gene Sciences raises $8M w/ Jim Blair | |
| Sep 9, 2016 | Gene editing star CRISPR Therapeutics files for $90M IPO | Emmanuelle Charpentier. Credit: Bianca Fioretti, Hallbauer & Fioretti
In one of the most highly anticipated biotech IPOs of the year, CRISPR Therapeutics has filed its S-1 outlining its plans to raise $90 million fro... |
| May 27, 2014 | Spark Therapeutics’ late-stage gene therapy for inherited blindness takes a $73M step forward | Developed at CHOP’s Center for Cellular and Molecular Therapeutics, the therapy uses a neutralized virus as a vehicle to deliver a function gene to targeted cells in the eye. Once there, it enables production of a critical protein that’s mi... |
| Nov 20, 2013 | Gene therapy startup launches with $5M and eyes toward a better treatment for hemophilia | Currently Dimension is working on IND-enabling studies of a drug candidate for hemophilia B, a hereditary bleeding disorder characterized by a lack of one of the proteins needed to form blood clots in the body. It can cause a person to expe... |
| Jul 27, 2012 | Fundraising: Gene therapy firm targeting sickle cell anemia raises $60M | Product: Gene therapy to target sickle cell anemia, beta-thalassemia and childhood cerebral adrenoleukodystrophy
Money raised: $60 million in series D; at least $76 million in previous rounds based on press releases and U.S. Securities and ... |
